BEAUTYFARM MED (02373) Income Statement & Earnings

18.910
-0.300-1.56%

15min DelayMarket Closed Aug 25 15:59 CST

4.69BMarket Cap13.35P/E (TTM)

BEAUTYFARM MED (02373) Income Statement

Cumulative·All

YOY

Hide blank lines

Currency: CNY

2025/FY

2025/H1

2024/FY

2024/H1

2023/FY

2023/H1

2022/FY

2022/H1

2021/FY

2021/H1

2020/FY

2019/FY

Total Revenue

+16.65%3.00B

+28.24%1.46B

+19.91%2.57B

+9.72%1.14B

+31.16%2.15B

+41.20%1.04B

-8.16%1.64B

-12.25%734.32M

+18.46%1.78B

--836.83M

+7.02%1.50B

--1.40B

Operating Revenue

+16.65%3.00B

+28.24%1.46B

+19.91%2.57B

+9.72%1.14B

+31.16%2.15B

+41.20%1.04B

-8.16%1.64B

-12.25%734.32M

+18.46%1.78B

--836.83M

+7.02%1.50B

--1.40B

Cost of Revenue

-10.60%-1.53B

-22.49%-739.23M

-18.34%-1.38B

-8.01%-603.49M

-27.29%-1.17B

-32.95%-558.76M

+3.10%-917.57M

+6.16%-420.29M

-17.89%-946.95M

---447.88M

-15.34%-803.27M

---696.41M

Cost of Goods Sold

-10.60%-1.53B

-22.49%-739.23M

-18.34%-1.38B

-8.01%-603.49M

-27.29%-1.17B

-32.95%-558.76M

+3.10%-917.57M

+6.16%-420.29M

-17.89%-946.95M

---447.88M

-15.34%-803.27M

---696.41M

Gross Profit

+23.69%1.47B

+34.74%719.79M

+21.79%1.19B

+11.73%534.20M

+36.12%977.10M

+52.25%478.11M

-13.91%717.84M

-19.26%314.03M

+19.11%833.79M

--388.95M

-1.17%700.02M

--708.34M

Operating Expense

-16.60%-1.04B

-31.49%-509.14M

-21.53%-888.89M

-10.60%-387.20M

-19.12%-731.39M

-15.83%-350.10M

-3.85%-614.00M

-11.75%-302.26M

-17.03%-591.25M

---270.47M

+2.82%-505.23M

---519.92M

Selling Expenses

-11.47%-514.71M

-32.21%-250.80M

-22.10%-461.75M

-13.65%-189.70M

-31.66%-378.17M

-38.82%-166.92M

+4.09%-287.23M

+7.75%-120.24M

-10.70%-299.46M

---130.34M

+2.68%-270.52M

---277.97M

Administrative Expenses

-22.90%-476.95M

-30.70%-236.71M

-21.91%-388.09M

-9.21%-181.11M

-7.76%-318.35M

+0.85%-165.84M

-8.44%-295.43M

-26.87%-167.26M

-21.60%-272.45M

---131.84M

+5.61%-224.06M

---237.38M

Research and Development Expenses

-16.40%-41.94M

-29.12%-21.00M

-5.76%-36.03M

+5.37%-16.26M

-9.25%-34.07M

-14.62%-17.18M

-72.98%-31.19M

-93.42%-14.99M

-42.30%-18.03M

---7.75M

-38.59%-12.67M

---9.14M

Impairment and Provision

+7.02%-2.81M

-398.43%-633.00K

-279.52%-3.02M

+19.11%-127.00K

-413.55%-796.00K

-168.26%-157.00K

+88.13%-155.00K

+141.82%230.00K

-164.81%-1.31M

---550.00K

-55.92%2.02M

--4.57M

-Impairment Losses of Other Assets

+7.02%-2.81M

-398.43%-633.00K

-279.52%-3.02M

+19.11%-127.00K

-413.55%-796.00K

-168.26%-157.00K

+88.13%-155.00K

+141.82%230.00K

-164.81%-1.31M

---550.00K

-55.92%2.02M

--4.57M

Special Items of Operating Income

+16.07%24.05M

-16.16%13.47M

-54.55%20.72M

-41.49%16.07M

-5.54%45.58M

+8.65%27.46M

+35.93%48.25M

+23.15%25.28M

+91.53%35.50M

--20.52M

-1.17%18.53M

--18.75M

Operating Profit

+42.78%459.52M

+37.44%224.12M

+10.48%321.82M

+4.89%163.07M

+91.52%291.29M

+319.65%155.47M

-45.30%152.09M

-73.35%37.05M

+30.33%278.04M

--139.00M

+2.97%213.33M

--207.18M

Financing Income

-3.82%22.71M

+5.65%12.44M

+8.14%23.62M

+14.48%11.77M

+605.79%21.84M

+890.56%10.28M

+141.15%3.09M

+71.29%1.04M

+13.14%1.28M

--606.00K

+33.10%1.13M

--852.00K

Financing Cost

-16.72%-32.16M

-10.42%-15.85M

-11.06%-27.56M

-16.74%-14.35M

-0.40%-24.81M

-2.07%-12.29M

-2.05%-24.71M

+2.27%-12.05M

+6.60%-24.22M

---12.33M

+8.26%-25.93M

---28.26M

Share of Profits of Associates

----

---51.00K

----

Pretax Profit

+41.58%450.07M

+37.52%220.71M

+10.27%317.88M

+4.58%160.49M

+120.94%288.27M

+489.31%153.46M

-48.85%130.48M

-79.54%26.04M

+35.31%255.10M

--127.28M

+4.88%188.53M

--179.76M

Tax

-67.86%-109.79M

-45.07%-49.94M

-12.52%-65.41M

-6.45%-34.42M

-191.48%-58.13M

-422.32%-32.34M

+57.35%-19.94M

+72.08%-6.19M

-28.66%-46.76M

---22.18M

-12.39%-36.35M

---32.34M

Net Profit

+34.77%340.28M

+35.46%170.77M

+9.71%252.48M

+4.08%126.07M

+108.21%230.14M

+510.21%121.12M

-46.95%110.53M

-81.12%19.85M

+36.90%208.34M

--105.11M

+3.23%152.19M

--147.42M

Profit from Continuing Operations

+34.77%340.28M

+35.46%170.77M

+9.71%252.48M

+4.08%126.07M

+108.21%230.14M

+510.21%121.12M

-46.95%110.53M

-81.12%19.85M

+36.90%208.34M

--105.11M

+3.23%152.19M

--147.42M

Minority Interests

-5.43%22.71M

+41.74%15.09M

+65.85%24.02M

+14.60%10.65M

+95.10%14.48M

+96.57%9.29M

-50.07%7.42M

-42.08%4.73M

+1112.56%14.87M

--8.16M

-82.72%1.23M

--7.09M

Net Income to Parent Company

+39.00%317.56M

+34.88%155.68M

+5.94%228.46M

+3.21%115.42M

+109.15%215.66M

+639.47%111.83M

-46.71%103.11M

-84.40%15.12M

+28.16%193.48M

--96.95M

+7.58%150.96M

--140.33M

Net Income to Common Stockholders

+39.00%317.56M

+34.88%155.68M

+5.94%228.46M

+3.21%115.42M

+109.15%215.66M

+639.47%111.83M

-46.71%103.11M

-84.40%15.12M

+28.16%193.48M

--96.95M

+7.58%150.96M

--140.33M

Basic EPS

+39.39%1.38

+36.00%0.68

+5.32%0.99

+2.04%0.50

+80.77%0.94

+512.50%0.49

-46.39%0.52

-91.75%0.08

-35.76%0.97

--0.97

+7.09%1.51

--1.41

Diluted EPS

+38.38%1.37

+36.00%0.68

+5.32%0.99

+2.04%0.50

+80.77%0.94

+512.50%0.49

-46.39%0.52

-91.75%0.08

-35.76%0.97

--0.97

+7.09%1.51

--1.41

Deadline

Dec 31, 2025

Jun 30, 2025

Dec 31, 2024

Jun 30, 2024

Dec 31, 2023

Jun 30, 2023

Dec 31, 2022

Jun 30, 2022

Dec 31, 2021

Jun 30, 2021

Dec 31, 2020

Dec 31, 2019

Accounting Standard

HKAS

Audit Opinions

	2025/FY	2025/H1	2024/FY	2024/H1	2023/FY	2023/H1	2022/FY	2022/H1	2021/FY	2021/H1	2020/FY	2019/FY

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More

牛牛課堂

Oct 13, 2025 18:05

[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?

Food流油

Apr 14, 2025 15:43

"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"